The use of targeted, biologic (immunotherapy) & other forms of therapies administered to treat cancer through oncology drugs is known as cancer therapeutics. The global cancer therapeutics market size was valued at $98,900 million in 2018 and is estimated to reach at $180,193 million by 2026, registering a CAGR of 7.7% from 2019 to 2026.
Upsurge in collaboration between pharmaceutical companies, rise in cancer awareness & availability of oncology drugs, increase in cancer funding & research, and growth in geriatric population are the key factors that augment the growth of the cancer therapeutics market. Furthermore, rise in prevalence of cancer cases is expected to boost the market growth.
However, adverse effects associated with cancer therapeutics market and high costs associated with oncology drug development are some of the factors that impede the market growth. Conversely, the high potential of emerging economies and increase in demand for personalized medicine is expected to provide new opportunities for the market players in future.
The cancer therapeutics market is segmented based on application, top selling drugs, and region. Based on application, the market is divided into blood cancer, lung cancer, colorectal cancer, prostate cancer, breast cancer, cervical cancer, head & neck cancer, glioblastoma, malignant meningioma, mesothelioma, melanoma, and others. By top selling drugs, it is categorized into Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, Temodar and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
KEY MARKET SEGMENTS
By Application
o Blood Cancer
o Lung Cancer
o Colorectal Cancer
o Prostate Cancer
o Breast Cancer
o Cervical Cancer
o Head and Neck Cancer
o Glioblastoma
o Malignant Meningioma
o Mesothelioma
o Melanoma
o Others
By Top Selling Drugs
o Revlimid
o Avastin
o Herceptin
o Rituxan
o Opdivo
o Gleevec
o Velcade
o Imbruvica
o Ibrance
o Zytiga
o Alimta
o Xtandi
o Tarceva
o Perjeta
o Temodar
o Others
By Region
o North America
The list of key players operating in this market include:
The other players included in the value chain analysis (and not included in the report) include:
Upsurge in collaboration between pharmaceutical companies, rise in cancer awareness & availability of oncology drugs, increase in cancer funding & research, and growth in geriatric population are the key factors that augment the growth of the cancer therapeutics market. Furthermore, rise in prevalence of cancer cases is expected to boost the market growth.
However, adverse effects associated with cancer therapeutics market and high costs associated with oncology drug development are some of the factors that impede the market growth. Conversely, the high potential of emerging economies and increase in demand for personalized medicine is expected to provide new opportunities for the market players in future.
The cancer therapeutics market is segmented based on application, top selling drugs, and region. Based on application, the market is divided into blood cancer, lung cancer, colorectal cancer, prostate cancer, breast cancer, cervical cancer, head & neck cancer, glioblastoma, malignant meningioma, mesothelioma, melanoma, and others. By top selling drugs, it is categorized into Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, Temodar and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
- This report entails a detailed quantitative market analysis from 2018 to 2026 to identify the prevailing opportunities along with strategic assessment of the global cancer therapeutics market.
- Cancer therapeutics market size and market estimations are based on a comprehensive analysis of the applications, top selling drugs, and developments in the industry.
- An in-depth analysis based on region assists to understand the regional market and facilitate the strategic business planning.
- The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.
KEY MARKET SEGMENTS
By Application
o Blood Cancer
o Lung Cancer
o Colorectal Cancer
o Prostate Cancer
o Breast Cancer
o Cervical Cancer
o Head and Neck Cancer
o Glioblastoma
o Malignant Meningioma
o Mesothelioma
o Melanoma
o Others
By Top Selling Drugs
o Revlimid
o Avastin
o Herceptin
o Rituxan
o Opdivo
o Gleevec
o Velcade
o Imbruvica
o Ibrance
o Zytiga
o Alimta
o Xtandi
o Tarceva
o Perjeta
o Temodar
o Others
By Region
o North America
- U.S.
- Canada
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Japan
- China
- India
- Australia
- South Korea
- Taiwan
- Rest of Asia-Pacific
- Latin America
- Middle-East
- Africa
The list of key players operating in this market include:
- F. Hoffmann-La Roche AG
- Bristol-Myers Squibb Company
- AbbVie, Inc.
- Johnson & Johnson
- Celgene Corporation
- Astellas Pharma, Inc.
- Pfizer, Inc.
- Novartis AG
- Merck KGaA
- Eli Lilly and Company
The other players included in the value chain analysis (and not included in the report) include:
- AstraZeneca plc
- Bayer AG
- Takeda Pharmaceutical Company Limited
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: CANCER THERAPEUTICS MARKET, APPLICATION
CHAPTER 5: CANCER THERAPEUTICS MARKET, BY TOP SELLING DRUGS
CHAPTER 6: CANCER THERAPEUTICS MARKET, BY REGION
CHAPTER 7: COMPANY PROFILES
Executive Summary
According to the report titled,'Cancer Therapeutics Market by Application and End User: Global Opportunity Analysis and Industry Forecast, 2019 - 2026.'The global cancer therapeutics market size was valued at $98,900 million in 2018, and is projected to reach $180,193 million by 2026, at a CAGR of 7.7% from 2019-2026. The market is driven by factors such as development of novel cancer therapeutics and surge in cancer awareness & availability of oncology drugs in the developing markets.Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging economies provide lucrative opportunities to the market. However, adverse effects related to cancer therapeutics and high costs associated with oncology drugs impede the growth of the cancer therapeutics market.
Recent progress in biological therapies have widened the scale of therapeutic targets for treatment of cancer with the identification of tumor cell specific genes. Immunotherapies/biologics are emerging as the potential therapies to find a permanent cure for various cancer types among various cancer therapeutics.
Among the different applications, lung cancer nearly occupied one-fifth share in the global cancer therapeutics market in 2018. This can be attributed to the increase in prevalence of lung cancer in both developed and developing economies. Furthermore, pharmaceutical companies are developing new and improved drugs to tackle the burden of this disease.
The cancer therapeutics market trends are analyzed based on application, top selling drugs, and region. Based on application, the market is divided into blood cancer, lung cancer, colorectal cancer, prostate cancer, breast cancer, cervical cancer, head & neck cancer, glioblastoma, malignant meningioma, mesothelioma, melanoma, and others. By top selling drugs, it is categorized into Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, Temodar and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings of the Cancer Therapeutics Market:
Europe accounted for more nearly two-sevenths of the cancer therapeutics market share in 2018.
The prostate cancer application segment is anticipated to grow with the highest CAGR throughout the forecast period.
Revlimid brand occupied the largest share in the top selling drugs segment in 2018.
Asia-Pacific is anticipated to grow at the highest rate in the cancer therapeutics market during the analysis period.
North America was the leading revenue contributor to the global market in 2018, owing to high adoption rate of cancer therapeutics. North America occupied more than half of the total market share in 2018. However, Asia-Pacific is expected to grow at the highest CAGR of 10.4% from 2019 to 2026, owing to increase in disposable income; surge in research, development, & innovation activities; and growth in awareness of cancer therapeutics.
Increase in competition and continuous technological advancements have led to enhancements in the product portfolio; hence, product approvals and product development are one of the key developmental strategies adopted by the market players in the global cancer therapeutics market. For instance, in November 2017, Merck and Pfizer launched the cancer drug Bavencio (avelumab), in the UK for the treatment of the rare, aggressive skin cancer metastatic Merkel Cell Carcinoma (mMCC). Similarly, in April 2018, the European Commission (EC) approved Pfizer's Mylotarg (gemtuzumab ozogamicin) in combination with daunorubicin and cytarabine for the treatment of patients aged 15 years and above with previously untreated, de novo, CD33-positive acute myeloid leukemia (AML), except acute promyelocytic leukemia (APL).
Similarly, different collaborations and agreements have also shaped the competitive landscape of the global cancer therapeutics industry. In December 2017, Janssen entered into a worldwide collaboration and license agreement with Legend Biotech USA Inc. and Legend Biotech Ireland Limited, both subsidiaries of Genscript Biotech Corporation, to develop, manufacture, and commercialize a chimeric antigen receptor (CAR) T-cell drug candidate, LCAR-B38M, which specifically targets the B-cell maturation antigen (BCMA). Likewise, in April 2018, Pfizer and the U.S. based Allogene Therapeutics collaborated to develop donor-derived CAR T-cell therapies.
The report provides an extensive competitive analysis and profiles of the key market players such as F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, AbbVie, Inc., Johnson & Johnson, Celgene Corporation, Astellas Pharma, Inc., Pfizer, Inc., Novartis AG, Merck KGaA, and Eli Lilly and Company. The other players in the value chain (not included in the report) include AstraZeneca plc, Bayer AG, and Takeda Pharmaceutical Company Limited.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 261 |
| Published | July 2019 |
| Forecast Period | 2018 - 2026 |
| Estimated Market Value ( USD | $ 98900 million |
| Forecasted Market Value ( USD | $ 180193 million |
| Compound Annual Growth Rate | 7.8% |
| Regions Covered | Global |
